相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The next tier of EGFR resistance mutations in lung cancer
Hannah L. Tumbrink et al.
ONCOGENE (2021)
Transient deSUMOylation of IRF2BP proteins controls early transcription in EGFR signaling
Sina Barysch et al.
EMBO REPORTS (2021)
Targeting metastatic cancer
Karuna Ganesh et al.
NATURE MEDICINE (2021)
LncRNA TINCR favors tumorigenesis via STAT3-TINCR-EGFR-feedback loop by recruiting DNMT1 and acting as a competing endogenous RNA in human breast cancer
Qin Wang et al.
CELL DEATH & DISEASE (2021)
Circular RNA-encoded oncogenic E-cadherin variant promotes glioblastoma tumorigenicity through activation of EGFR-STAT3 signalling
Xinya Gao et al.
NATURE CELL BIOLOGY (2021)
Structure-function analysis of oncogenic EGFR Kinase Domain Duplication reveals insights into activation and a potential approach for therapeutic targeting
Zhenfang Du et al.
NATURE COMMUNICATIONS (2021)
Detection of EGFR-SEPT14 fusion in cell-free DNA of a patient with advanced gastric cancer: A case report
Boyeon Kim et al.
WORLD JOURNAL OF CLINICAL CASES (2021)
The Hippo Tumor Suppressor Pathway (YAP/TAZ/TEAD/MST/LATS) and EGFR-RAS-RAF-MEK in cancer metastasis
Mohammad Reza Zinatizadeh et al.
GENES & DISEASES (2021)
A Rare EGFR-SEPT14 Fusion in a Patient with Colorectal Adenocarcinoma Responding to Erlotinib
Yong Li et al.
ONCOLOGIST (2020)
TGFβ and EGF signaling orchestrates the AP-1-and p63 transcriptional regulation of breast cancer invasiveness
Anders Sundqvist et al.
ONCOGENE (2020)
Regulation of Collective Metastasis by Nanolumenal Signaling
Emma D. Wrenn et al.
CELL (2020)
Hedgehog Signaling and Truncated GLI1 in Cancer
Daniel Doheny et al.
CELLS (2020)
EGFRvIII uses intrinsic and extrinsic mechanisms to reduce glioma adhesion and increase migration
Afsheen Banisadr et al.
JOURNAL OF CELL SCIENCE (2020)
Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study
Giulia Bon et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2020)
Transcriptomic and ChIP-sequence interrogation of EGFR signaling in HER2+breast cancer cells reveals a dynamic chromatin landscape and S100 genes as targets
Miguel Nava et al.
BMC MEDICAL GENOMICS (2019)
The circRNA-microRNA code: emerging implications for cancer diagnosis and treatment
Lorena Verduci et al.
MOLECULAR ONCOLOGY (2019)
Adaptive mutability of colorectal cancers in response to targeted therapies
Mariangela Russo et al.
SCIENCE (2019)
A Convergence-Based Framework for Cancer Drug Resistance
David J. Konieczkowski et al.
CANCER CELL (2018)
Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer
Suresh S. Ramalingam et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
J. -C. Soria et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
SILAC identifies LAD1 as a filamin-binding regulator of actin dynamics in response to EGF and a marker of aggressive breast tumors
Lee Roth et al.
SCIENCE SIGNALING (2018)
SILAC identifies LAD1 as a filamin-binding regulator of actin dynamics in response to EGF and a marker of aggressive breast tumors
Lee Roth et al.
SCIENCE SIGNALING (2018)
Long Noncoding RNA NEAT1, Regulated by the EGFR Pathway, Contributes to Glioblastoma Progression Through the WNT/β-Catenin Pathway by Scaffolding EZH2
Qun Chen et al.
CLINICAL CANCER RESEARCH (2018)
HER2 and EGFR Overexpression Support Metastatic Progression of Prostate Cancer to Bone
Kathleen C. Day et al.
CANCER RESEARCH (2017)
Proteomic analysis of ovarian cancer cells during epithelial-mesenchymal transition (EMT) induced by epidermal growth factor (EGF) reveals mechanisms of cell cycle control
Mariana Lopes Grassi et al.
JOURNAL OF PROTEOMICS (2017)
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer
T. S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Epigenetic mechanisms underlie the crosstalk between growth factors and a steroid hormone
Yehoshua Enuka et al.
NUCLEIC ACIDS RESEARCH (2017)
A loop of cancer-stroma-cancer interaction promotes peritoneal metastasis of ovarian cancer via TNFα-TGFα-EGFR
T-S Lau et al.
ONCOGENE (2017)
The EGFR/miR-338-3p/EYA2 axis controls breast tumor growth and lung metastasis
Yingchun Liang et al.
CELL DEATH & DISEASE (2017)
Actin stress fiber organization promotes cell stiffening and proliferation of pre-invasive breast cancer cells
Sandra Tavares et al.
NATURE COMMUNICATIONS (2017)
An Acquired HER2T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer
Ariella B. Hanker et al.
CANCER DISCOVERY (2017)
Protein biomarkers predictive for response to anti-EGFR treatment in RAS wild-type metastatic colorectal carcinoma
Astrid Lievre et al.
BRITISH JOURNAL OF CANCER (2017)
EGFR/c-myc axis regulates TGFβ/Hippo/Notch pathway via epigenetic silencing miR-524 in gliomas
Kai Zhao et al.
CANCER LETTERS (2017)
Emerging Biological Principles of Metastasis
Arthur W. Lambert et al.
CELL (2017)
TTCA: an R package for the identification of differentially expressed genes in time course microarray data
Marco Albrecht et al.
BMC BIOINFORMATICS (2017)
Circular RNAs are long-lived and display only minimal early alterations in response to a growth factor
Yehoshua Enuka et al.
NUCLEIC ACIDS RESEARCH (2016)
MALT1 is required for EGFR-induced NF-κB activation and contributes to EGFR-driven lung cancer progression
D. Pan et al.
ONCOGENE (2016)
LIMT is a novel metastasis inhibiting lncRNA suppressed by EGF and downregulated in aggressive breast cancer
Aldema Sas-Chen et al.
EMBO MOLECULAR MEDICINE (2016)
Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition
Aaron N. Hata et al.
NATURE MEDICINE (2016)
Mutational and network level mechanisms underlying resistance to anti-cancer kinase inhibitors
Maicol Mancini et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2016)
Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer
Vincenzo Sforza et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2016)
The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis
Yue-Lun Zhang et al.
Oncotarget (2016)
The role of epithelial to mesenchymal transition in resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
Kristine Raaby Jakobsen et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2016)
Mammalian Target of Rapamycin: Its Role in Early Neural Development and in Adult and Aged Brain Function
Carla Garza-Lombo et al.
FRONTIERS IN CELLULAR NEUROSCIENCE (2016)
EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients
D. Planchard et al.
ANNALS OF ONCOLOGY (2015)
A Structural Perspective on the Regulation of the Epidermal Growth Factor Receptor
Erika Kovacs et al.
ANNUAL REVIEW OF BIOCHEMISTRY, VOL 84 (2015)
PI3K-independent mTOR activation promotes lapatinib resistance and IAP expression that can be effectively reversed by mTOR and Hsp90 inhibition
Samuel W. Brady et al.
CANCER BIOLOGY & THERAPY (2015)
Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models
Catherine A. Eberlein et al.
CANCER RESEARCH (2015)
Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy
Mario Giuliano et al.
CLINICAL CANCER RESEARCH (2015)
The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies
Matthew J. Niederst et al.
CLINICAL CANCER RESEARCH (2015)
Navigator-3, a modulator of cell migration, may act as a suppressor of breast cancer progression
Hadas Cohen-Dvashi et al.
EMBO MOLECULAR MEDICINE (2015)
The Hippo/YAP pathway interacts with EGFR signaling and HPV oncoproteins to regulate cervical cancer progression
Chunbo He et al.
EMBO MOLECULAR MEDICINE (2015)
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M
Kenneth S. Thress et al.
NATURE MEDICINE (2015)
AZD9291 in EGFR Inhibitor-Resistant Non-Small-Cell Lung Cancer
Pasi A. Jaenne et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Synaptojanin 2 is a druggable mediator of metastasis and the gene is overexpressed and amplified in breast cancer
Nir Ben-Chetrit et al.
SCIENCE SIGNALING (2015)
EGF induces microRNAs that target suppressors of cell migration: miR-15b targets MTSS1 in breast cancer
Merav Kedmi et al.
SCIENCE SIGNALING (2015)
EGFR and NF-κB: partners in cancer
Kateryna Shostak et al.
TRENDS IN MOLECULAR MEDICINE (2015)
Synaptojanin 2 is a druggable mediator of metastasis and the gene is overexpressed and amplified in breast cancer
Nir Ben-Chetrit et al.
SCIENCE SIGNALING (2015)
EGF induces microRNAs that target suppressors of cell migration: miR-15b targets MTSS1 in breast cancer
Merav Kedmi et al.
SCIENCE SIGNALING (2015)
Cancer: Evolution Within a Lifetime
Marco Gerlinger et al.
ANNUAL REVIEW OF GENETICS, VOL 48 (2014)
ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics
Carlos L. Arteaga et al.
CANCER CELL (2014)
Mesenchymal Chemotaxis Requires Selective Inactivation of Myosin II at the Leading Edge via a Noncanonical PLCγ/PKCα Pathway
Sreeja B. Asokan et al.
DEVELOPMENTAL CELL (2014)
Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies
Simonetta M. Leto et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2014)
The EGFR Family: Not So Prototypical Receptor Tyrosine Kinases
Mark A. Lemmon et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2014)
The Somatic Genomic Landscape of Glioblastoma
Cameron W. Brennan et al.
CELL (2013)
Epidermal Growth-Factor - Induced Transcript Isoform Variation Drives Mammary Cell Migration
Wolfgang J. Koestler et al.
PLOS ONE (2013)
Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies
Ariella B. Hanker et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer
Hiroyuki Yasuda et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer
Alberto Bardelli et al.
CANCER DISCOVERY (2013)
Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas
A. Gallardo et al.
BRITISH JOURNAL OF CANCER (2012)
mTOR Signaling in Growth Control and Disease
Mathieu Laplante et al.
CELL (2012)
Hedgehog-EGFR cooperation response genes determine the oncogenic phenotype of basal cell carcinoma and tumour-initiating pancreatic cancer cells
Markus Eberl et al.
EMBO MOLECULAR MEDICINE (2012)
EGR1 and the ERK-ERF axis drive mammary cell migration in response to EGF
Gabi Tarcic et al.
FASEB JOURNAL (2012)
Cooperative Hedgehog-EGFR signaling
Doris Mangelberger et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2012)
GENCODE: The reference human genome annotation for The ENCODE Project
Jennifer Harrow et al.
GENOME RESEARCH (2012)
MET Activation Mediates Resistance to Lapatinib Inhibition of HER2-Amplified Gastric Cancer Cells
Chin-Tung Chen et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rafael Rosell et al.
LANCET ONCOLOGY (2012)
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
Zhenfeng Zhang et al.
NATURE GENETICS (2012)
Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer
Clara Montagut et al.
NATURE MEDICINE (2012)
Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1
Kadoaki Ohashi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR-Mutant Lung Cancers That Lack the Second-Site EGFRT790M Mutation
Ken Takezawa et al.
CANCER DISCOVERY (2012)
Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met
Kelly L. Mueller et al.
BREAST CANCER RESEARCH (2012)
The ERBB network: at last, cancer therapy meets systems biology
Yosef Yarden et al.
NATURE REVIEWS CANCER (2012)
Twist1-Induced Invadopodia Formation Promotes Tumor Metastasis
Mark A. Eckert et al.
CANCER CELL (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Feedback regulation of EGFR signalling: decision making by early and delayed loops
Roi Avraham et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2011)
Mechanistic insights into the activation of oncogenic forms of EGF receptor
Zhihong Wang et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2011)
Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase
Joan T. Garrett et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
Kimio Yonesaka et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Lecia V. Sequist et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
A Molecularly Annotated Platform of Patient-Derived Xenografts (Xenopatients) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer
Andrea Bertotti et al.
CANCER DISCOVERY (2011)
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sreenath V. Sharma et al.
CELL (2010)
Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer
Alberto Bardelli et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
X-Linked Inhibitor of Apoptosis Protein Inhibits Apoptosis in Inflammatory Breast Cancer Cells with Acquired Resistance to an ErbB1/2 Tyrosine Kinase Inhibitor
Katherine M. Aird et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Tetsuya Mitsudomi et al.
LANCET ONCOLOGY (2010)
Roles for Growth Factors in Cancer Progression
Esther Witsch et al.
PHYSIOLOGY (2010)
EGF Decreases the Abundance of MicroRNAs That Restrain Oncogenic Transcription Factors
Roi Avraham et al.
SCIENCE SIGNALING (2010)
Evidence that Inositol Polyphosphate 4-Phosphatase Type II Is a Tumor Suppressor that Inhibits PI3K Signaling
Christina Gewinner et al.
CANCER CELL (2009)
Novel Mechanism of Lapatinib Resistance in HER2-Positive Breast Tumor Cells: Activation of AXL
Li Liu et al.
CANCER RESEARCH (2009)
Epithelial-Mesenchymal Transitions in Development and Disease
Jean Paul Thiery et al.
CELL (2009)
ErbB receptors and signaling pathways in cancer
Nancy E. Hynes et al.
CURRENT OPINION IN CELL BIOLOGY (2009)
PLC-γ1 and Rac1 Coregulate EGF-Induced Cytoskeleton Remodeling and Cell Migration
Siwei Li et al.
MOLECULAR ENDOCRINOLOGY (2009)
Random versus directionally persistent cell migration
Ryan J. Petrie et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2009)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer
F. R. Hirsch et al.
ONCOGENE (2009)
Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235
Pieter J. A. Eichhorn et al.
CANCER RESEARCH (2008)
Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells
David L. Shattuck et al.
CANCER RESEARCH (2008)
Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor-Activating Mutations
Seiji Yano et al.
CANCER RESEARCH (2008)
EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation
Torsten Trowe et al.
CLINICAL CANCER RESEARCH (2008)
A Mena Invasion Isoform Potentiates EGF-Induced Carcinoma Cell Invasion and Metastasis
Ulrike Philippar et al.
DEVELOPMENTAL CELL (2008)
Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer
Antonino Musolino et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Lapatinib resistance in HCT116 cells is mediated by elevated MCL-1 expression and decreased BAK activation and not by ERBB receptor kinase mutation
Aditi Pandya Martin et al.
MOLECULAR PHARMACOLOGY (2008)
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Cai-Hong Yun et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Derailed endocytosis: an emerging feature of cancer
Yaron Mosesson et al.
NATURE REVIEWS CANCER (2008)
The par-tiam1 complex controls persistent migration by stabilizing microtubule-dependent front-rear polarity
D. Michiel Pegtel et al.
CURRENT BIOLOGY (2007)
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer
Katrien Berns et al.
CANCER CELL (2007)
Defective ubiquitinylation of EGFR mutants of lung cancer confers prolonged signaling
K. Shtiegman et al.
ONCOGENE (2007)
Immediate-early and delayed primary response genes are distinct in function and genomic architecture
John W. Tullai et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
The MEK/ERK cascade: From signaling specificity to diverse functions
Yoav D. Shaul et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2007)
Regulation of MAPKs by growth factors and receptor tyrosine kinases
Menachem Katz et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2007)
Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma
Paul H. Huang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy
F. Di Fiore et al.
BRITISH JOURNAL OF CANCER (2007)
Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer
Maurizio Scaltriti et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
A module of negative feedback regulators defines growth factor signaling
Ido Amit et al.
NATURE GENETICS (2007)
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Jeffrey A. Engelman et al.
NATURE REVIEWS GENETICS (2006)
Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors
Katerina Politi et al.
GENES & DEVELOPMENT (2006)
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
A Lièvre et al.
CANCER RESEARCH (2006)
Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants
H Greulich et al.
PLOS MEDICINE (2005)
A Rac switch regulates random versus directionally persistent cell migration
R Pankov et al.
JOURNAL OF CELL BIOLOGY (2005)
EGFR gene amplification in breast cancer:: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations
R Bhargava et al.
MODERN PATHOLOGY (2005)
Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer
F Cappuzzo et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
W Pao et al.
PLOS MEDICINE (2005)
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib
W Pao et al.
PLOS MEDICINE (2005)
Ets ternary complex transcription factors
G Buchwalter et al.
GENE (2004)
Bacterial persistence as a phenotypic switch
NQ Balaban et al.
SCIENCE (2004)
EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib
W Pao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers:: an immunohistochemical and fluorescent in situ hybridization study
A Ooi et al.
MODERN PATHOLOGY (2004)
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
Y Nagata et al.
CANCER CELL (2004)
EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
JG Paez et al.
SCIENCE (2004)
A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors
J Wyckoff et al.
CANCER RESEARCH (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Cdc42 regulates GSK-3β and adenomatous polyposis coli to control cell polarity
S Etienne-Manneville et al.
NATURE (2003)
A mutant EGF-receptor defective in ubiquitylation and endocytosis unveils a role for Grb2 in negative signaling
H Waterman et al.
EMBO JOURNAL (2002)
Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin)
YH Lu et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2001)
Untangling the ErbB signalling network
Y Yarden et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2001)
分享论文
